



FROM DOSIMETRY TO BIOLOGICAL EFFECT: RADIOBIOLOGY AS GUIDE TO CLINICAL PRACTICE IN NUCLEAR MEDICINE

Co-organized with COST BM0607 – Final Action congress

Web site: www.nuclearmedicinediscovery.org

Site: Sorrento, Italy

Date: November 5-8, 2011

CME: 18 European credits

Teaching material: editing of a book with the text of lectures and of abstracts of scientific presentation.

Promoting committee

Marco Chianelli, Rome, Italy
Luigi Mansi, Naples, Italy
Massimo Salvatori, Rome, Italy
Alberto Signore, Rome, Italy

Practical Course

Anna Giovanetti, Rome, Italy
Antonella Sgura, Rome, Italy

Scientific committee

Mauro Belli, Rome, Italy
Lisa Bodei, Milan, Italy
Marta Cremonesi, Milan, Italy
Marion de Jong, Rotterdam, The Netherlands
Rudi Dierckx, Groningen, The Netherlands
Massimo Dottorini, Perugia, Italy
Glenn Flux, London, UK
Anna Giovanetti, Rome, Italy
Stephen J. Mather, London, UK
Andrea Soricelli, Naples, Italy
Hubert Thierens, Gent, Belgium
Gregory Wiseman, Rochester, USA

under the auspices of



sponsored by



Saturday 5th November 2011

14:00-15:15 Registration

15:15-15:30 Welcome

Marco Chianelli, Luigi Mansi, Massimo Salvatori, Alberto Signore.

15:30-16:15 Opening lecture

Role of Radiobiology in low level radiation risk assessment: status, perspectives and research needs.

Mauro Belli, Rome, Italy

Session 1 - Introduction to radiobiology for nuclear medicine

16:15-16:45 Radiobiology and diagnostic nuclear medicine similarities and differences with respect to radiology

Marco Chianelli, Rome, Italy

16:45-17:15 Radiobiology and therapeutic nuclear medicine similarities and differences with respect to EBRT

Cecilia Arrichiello, Naples, Italy

17:15-17:45 *Coffee Break*

17:45-18:15 Low doses and non targeted effects: genomic instability, bystander effect, adaptive response

Anna Giovanetti, Rome, Italy

18:15-18:45 From markers of exposure to markers of risk

Marco Durante, Germany

18:45-19:15 Round table: Linear no threshold hypothesis does it apply to low doses in nuclear medicine?

chair leaders: *Mauro Belli, Marco Durante*

19:30-21:00 *Welcome cocktail*

Sunday 6th November 2011

Session 2 - Radiation risk for patients, staff and population

- 09:00-09:30 Risk assessment due to ionizing radiation:
conceptual approach for radiological protection purposes
Roberto Moccaldi, Rome, Italy
- 09:30-10:00 Radiation exposure to embryo-fetus and newborn child
Marie Claire Cantone, Milan, Italy
- 10:00-10:30 Use of biologic dosimetry for radiation risk assessment
Anne Vral, Gent, Belgium
- 10:30-11:00 *Coffee Break*
- 11:00-11:30 Risk in SPET and PET diagnostic nuclear medicine
Marco Chianelli, Rome, Italy
- 11:30-12:00 Risk in therapeutic Nuclear Medicine
Marta Cremonesi, Milan, Italy
- 12:00-12:30 Round table: Radionuclide therapy and radioprotection: time for a revision?
chair leaders: *Marco Chianelli, Massimo Salvatori*
- 12:30-14:00 *Lunch*

Oral presentations

Session A: Radiopharmacy Chairmen

- 14:00-14:12 NEW METHOD FOR ⁴⁷SC PRODUCTION IN NUCLEAR REACTOR
B.Bartoś, A.Majkowska, A.Kasperek, A.Bilewicz
- 14:12-14:24 PREPARATION AND QUALITY CONTROL OF ⁹⁰Y-DOTATATE AND ¹⁷⁷LU-DOTATATE FOR CLINICAL APPLICATION IN SERBIA
D.Djokic, N.Nikolic, Dj.Petrovic, D.Stankovic, R.Mikolajczak, D. Pawlak, M.Matovic, M. Jeremic
- 14:24-14:36 EFFECTIVENESS OF QUENCHERS TO PREVENT RADIOLYSES OF ¹¹¹IN OR ¹⁷⁷LU LABELLED PEPTIDES, SUCH AS CCK AND GRP ANALOGS; OPTIMALIZATION TO MAINTAIN RADIOCHEMICAL PURITY
Erik de Blois, Ho Sze Chan, Rory de Zanger, Dik Kwekkeboom and Wouter A.P. Breeman.
- 14:36-14:48 METHOD FOR POST-ELUTION CONCENTRATION AND ACIDITY REDUCTION OF ELUATE OBTAINED FROM SNO₂ BASED ⁶⁸GE/⁶⁸GA GENERATOR.
Dariusz Pawlak, Wioletta Wojdowska, Renata Mikolajczak
- 14:48-15:00 RADIOCHEMICAL PURITY ASSESSMENT RETRIEVED FROM VARIOUS CHROMATOGRAPHIC SYSTEMS BASED ON DMSA COMPLEXES WITH ^{99m}Tc AND ¹⁸⁸RE AT (III) AND (V) OXIDATION STATES.
Dariusz Pawlak, Piotr Garnuszek, Michał Maurin, Drina Jankovic, Urszula Karczmarczyk, Renata Mikołajczak

15:00-15:12 EVALUATION OF DOTA-COUPLED MINIGASTRIN LIKE CONGENERS AND OUR FIRST EXPERIENCE WITH BI-213 LABELLING
Marko Kroselj, Petra Kolenc Peitl, Rosalba Mansi, MariaLuisa Tamma, Martin Behe, Tanja Gmeiner Stopar, Jean Claude Reubi and Helmut R. Maecke

Session B: Dosimetry

Chairmen

15:12-15:24 DEVELOPMENT OF A REAL TIME 90Y DOSIMETRY ASSESSMENT SYSTEM BASED ON BREMSSTRAHLUNG PINHOLE SPECT DURING LIVER-SIRT
Stephan Walrand, Stanislas Pauwels, François Jamar.

15:24-15:36 3D PATIENT-SPECIFIC DOSIMETRY IN PATIENTS ENROLLED FOR ¹⁷⁷Lu-DOTATOC PRRT
F.Fioroni, E.Grassi, V.D'Errico, E.Mezzenga, A.Filice, A.Versari, D.Salvo, M.Iori

15:36-15:48 MURINE S-FACTORS BASED ON MONTE-CARLO SIMULATION FOR THE REALISTIC MODEL MOBY FOR SEVERAL RADIONUCLIDES OF INTEREST IN μ -PET
T. Mauxion, J. Barbet, M. Bardiès

15:48-16:00 NANODOSIMETRY OF I-125 AUGER ELECTRONS
S. Pszona and A. Bantsar

16:00-16:12 STUDY OF THE RELATIONSHIP BETWEEN THE MEAN NUCLEUS ABSORBED DOSE AND THE BIOLOGICAL RESPONSE OF TUMOR CELLS EXPOSED TO ¹²⁵I-LABELED MONOCLONAL ANTIBODIES
Bérengère Piron, Nathalie Kersual, Nicolas Chouin, Manuel Bardiès, Nadège Gironis, Caroline Bascoul Mollevi, Isabelle Navarro-Teulon, André Pèlerin and Jean-Pierre Pouget

16:15-16:45 *Coffee Break*

Session C: Biological and genotoxic effects

Chairmen

16:45-16:57 IN VIVO CELLULAR GENOTOXICITY OF ¹⁸⁸RE-ANTI-VEGF-MAB ON NORMAL CELLS USING COMET ASSAY
Diana Savu, Valeria Lungu, Dana Niculae, Iuliana Gruia, Rodica Anghel, Cosmin Mustaciosu, Ileana Petcu

16:57-17:09 BIOLOGICAL EFFECTS ON NORMAL TISSUES FOLLOWING LOW DOSE ¹³¹I IRRADIATION; MICROARRAY AND GENE EXPRESSION ANALYSIS
Emil Schüller, Toshima Z. Parris, Nils Rudqvist, Khalil Helou, Eva Forssell-Aronsson

17:09-17:21 GLOBAL TRANSCRIPTIONAL RESPONSE ON MOUSE KIDNEY FOLLOWING INTERNAL IRRADIATION WITH ¹⁷⁷Lu-OCTREOTATE
Emil Schüller, Toshima Z. Parris, Nils Rudqvist, Khalil Helou, Eva Forssell-Aronsson

17:21-17:33 MOLECULAR ANALYSIS OF GENE POLYMORPHISMS AND RESPONSE TO RADIOIMMUNOTHERAPY: PRELIMINARY DATA
P. A. Erba, M. Sollini, C. Mazzanti, K. Zavaglia K, F. Lessi, S. Tomei, R. Boni, E. Lazzeri, A. Cataldi, C. Manfredi, G. Bevilacqua and G. Mariani

17:33-17:45 THE TRANSCRIPTIONAL RESPONSE TO IN VIVO ASTATINE-211 EXPOSURE OF MOUSE THYROIDS REVEALS DISTINCT ABSORBED DOSE-DEPENDENT PROFILES
Rudqvist N, Parris TZ, Schüller E, Helou K, Forssell-Aronsson E

- 17:45-17:57 IN VIVO IODINE-131 EXPOSURE REVEALS DISTINCT ABSORBED DOSE-DEPENDENT GENE EXPRESSION PROFILES IN MOUSE THYROID TISSUE
Rudqvist N, Parris TZ, Schüler E, Helou K, Forssell-Aronsson E
- 17:57-18:09 ASSESSMENT OF CYTOGENETIC AND GENOTOXIC EFFECTS OF CURCUMIN ON HUMAN LYMPHOCYTES *IN VITRO*
Natividad Sebastià, Miguel Almonacid, Juan Ignacio Villaescusa, Jose Miguel Soriano, Alegría Montoro
- Session D: Pre-clinical studies**
Chairmen
- 18:09-18:21 PITFALLS OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR IMAGING PERFORMED BY [LYS⁴⁰(AHX-HYNIC-^{99m}Tc/EDDA)NH₂]-EXENDIN-4.
Hubalewska-Dydejczyk A, Sowa-Staszczak A, Pach D, Jabrocka-Hybel A, Stefańska A, Tomaszuk M, Mikołajczak R, Janota B
- 18:21-18:33 PRECLINICAL EVALUATION OF ¹⁷⁷LU-DOTAM-EGF
Dana Niculae, Valeria Lungu, Rodica Anghel, Iuliana Gruia, Ioana Esanu and Ioan Ursu
- 18:33-18:45 *IN VITRO* BIOLOGICAL TESTING OF ¹⁸⁸RE-ANTI-VEGF ¹⁸⁸RE-ANTI-MUC1 ON TUMOR CELLS
Dana Niculae, Lorelei Brasoveanu, Diana Savu, Iuliana Gruia, Rodica Anghel, Ioana Esanu
- 18:45-18:57 INTRATUMORAL DISTRIBUTION OF RADIOLABELED MONOCLONAL ANTIBODY BR96 IN A SYNGENEIC RAT COLON CARCINOMA MODEL
Sophie E. Eriksson, Anders Örbom, Erika Elgström, Sven-Erik Strand, Jan Tennvall and Rune Nilsson
- 18:57-19:09 THE EFFECTS OF RECEPTOR AFFINITY OF SOMATOSTATIN-BASED RADIOPEPTIDES ON RADIOACTIVITY UPTAKE IN SOMATOSTATIN RECEPTOR-RICH ORGANS
A.Laznickova, M. Laznicek, H.R.Maecke
- 19:09-19:21 COMPARISON OF L-GLU VS. D-GLU ¹¹¹IN-DOTA COUPLED MINIGASTRIN CONGENERS FOR TARGETING OF THE GASTRIN RECEPTOR
Petra Kolenc Peitl¹, MariaLuisa Tamma², Marko Kroselj¹, Martin Behe³, Jean Claude Reubi⁴, Helmut R. Maecke^{2,3} and Rosalba Mansi^{2,3}
- 20:30-23:00 *Social Dinner*

Monday 7th November 2011

COST BM0607 WG1: Molecular targets for targeted radionuclide therapy

08:30-08:45 Jaques Barbet - coordinator report

08:45-09:00 BIOKINETICS AND PRELIMINARY DOSE ASSESSMENT OF [LYS⁴⁰(AHX-HYNIC-^{99m}Tc/EDDA)NH₂]-EXENDIN-4 FOR GLUCAGONLIKE PEPTIDE-1 RECEPTOR IMAGING.

Tomaszuk M, Sowa-Staszczak A, Mikołajczak R, Buziak-Bereza M, Lenda-Tracz W, Głowa B, Janota B, Hubalewska-Dydejczyk A

COST BM0607 WG3: Dosimetry and radiobiology

09:00-09:15 Glenn Flux, Mark Konijnenberg - coordinator report

09:15-09:30 A COMPARTMENTAL MODEL TO PREDICT HAEMATOLOGIC TOXICITY
Nicolas Sas, Julie Rousseau, Frédérique Nguyen, Alexandre Govignon, Jérôme Abadie, Jacques Barbet, Cecilia Hindorf

09:30-09:45 4D-SPECT/CT ACQUISITION IN 3D-DOSE CALCULATION AND DOSE PLANNING IN LU-177-PRRT FOR CLINICAL ROUTINE

Aki Kangasmäki, Joakim Pyry, Timo Kiljunen, Kalevi Kairemo

COST BM0607 WG4: Radionuclides

09:45-10:00 Renata Mikołajczak - coordinator report

10:00-10:15 DEVELOPMENT OF A 5 MCI ⁴⁴Ti/⁴⁴Sc RADIONUCLIDE GENERATOR FOR MOLECULAR IMAGING VIA PET

N. Loktionova, D.V. Filosofov, M. Pruszyński, F. Rösch

10:15-10:30 MEASURING SPECIFIC ACTIVITY OF LUTETIUM-177 (¹⁷⁷Lu) BY HPLC: AN ALTERNATIVE METHOD

Wouter AP Breeman, Erik de Blois, Rory de Zanger and Dik J Kwekkeboom.

10:30-10:45 COMPARATIVE EVALUATION OF ^{99m}Tc AND ¹¹¹In-LABELED GRP-ANALOGS: EFFECTS OF METAL CHELATE ON TUMOR AND RENAL UPTAKE
Marsouvanidis PJ, Nock BA, Kaloudi A, Tatsi A, Krenning EP, de Jong M, Maina T

10:45-11:15 *Coffee Break*

Session 3 - How to obtain maximum therapeutic efficacy and the best tolerability in radionuclide therapy

11:15-11:45 Use of radioprotectors in radionuclide therapy
Eugenio Iorio, Naples, Italy

11:45-12:15 Strategies to enhance efficacy of radionuclide treatment
Mark Konijnenberg, Rotterdam, The Netherlands

12:15-12:45 Treatment of hyperthyroidism: is it possible to predict the outcome in Graves' disease?
Claudio Traino, Pisa, Italy

12:45-14:15 *Lunch*

- 14:15-14:45 Tumour biology: choice of radiopharmaceutical in relation to the molecular and biological characteristics of the tumors
Marion de Jong, Rotterdam, The Netherlands
- 14:45-15:15 Peptide receptor radionuclide therapy
Lisa Bodei, Milan, Italy
- 15:15-15:45 Radionuclide treatment of liver tumours and metastases
Carlo Chiesa, Milan, Italy
- 15:45-16:15 Treatment of differentiated thyroid carcinomas: dosimetry and biological dosimetry for tailored treatment with maximum efficacy
Christoph Reiners, Wurzburg, Germany
- 16:15-16:45 Round table: Radionuclide therapy may and has to be more aggressive?
chair leaders: *Alberto Signore and Luigi Mansi*
- 16:45-17:15 *Coffee Break*

COST BM0607 WG2: New ligands and chemistry for targeted radionuclide therapy

- 17:15-17:30 John Mertens, Roger Schibli - coordinator report
- 17:30-17:45 EVALUATION OF FOLIC ACID RADIOCONJUGATE WITH IMPROVED IN VIVO PROPERTIES FOR FOLATE RECEPTOR-TARGETED RADIONUCLIDE TUMOR THERAPY
Cristina Müller, Villigen, Switzerland
- 17:45-18:00 MACROCYCLIC BISPHOSPHONATES FOR PET-IMAGING WITH ⁶⁸GA AND THERAPY WITH ¹⁷⁷LU OF BONE METASTASES
M. Meckel, Mainz, Germany

COST BM0607 WG5: Preclinical studies with radiolabelled peptides

- 18:00-18:15 Otto Boerman and Luigi Aloj- coordinator report
- 18:15-18:30 IMAGING SOMATOSTATIN RECEPTOR 2 GENE TRANSFER WITH POSITRON EMISSION TOMOGRAPHY IN MICE
Luigi Aloj
- 18:30-19:00 THERANOSTICS: GRP RECEPTOR TARGETING PEPTIDES AS AN EXAMPLE
Rosalba Mansi
- 19:00-19:15 ¹⁷⁶LU- VERSUS ¹⁷⁶YB-DERIVED ¹⁷⁷LU LABELLED TO DOTA, TYR³-OCTREOTATE FOR PRRT; FIRST DATA FROM PRECLINICAL STUDIES
Marleen Melis, Mark W. Konijnenberg, Saskia C. Berndsen, Wout A.P. Breeman, Erik de Blois, and Marion de Jong

Tuesday 8th November 2011

(Parallel sessions)

Session 4 - Practical course in biologic dosimetry (small hall)

09:00-13:00 Practical demonstration of relevant biotechniques for biological dosimetry:
a proposal for harmonized research protocols

- Aim, sensitivity and specificity of biological dosimetry
- Isolation of cells and supernatant
- Stocking and preparations of specimens
- Description of the techniques
- Reading and interpretations of results
- Limits, pitfalls, interferences

COST PROGRAMME Management Committee meeting

9:00-10:20 Coordinators' reports

10:20-10:50 *Coffee Break*

10:50-13:00 Coordinators' reports

13:00 -14:00 *Farewell cocktail*